NEW YORK, Aug. 29 – Xtrana has received a $400,000 Phase I NIH grant to develop nanofluidic nucleic acid preparation components, the company announced Wednesday.

The work will be done in collaboration with researchers at the University of New Mexico and Sandia National Laboratory.

The research builds on Broomfield, Colo.-based Xtrana’s Xtra Bind non-silica-based nucleic acid extraction technology. The application for the nanofluidic technology is to let users run assay panels for infectious diseases and other agents at the site of sample collection, the company said.